ViaDerma Inc (VDRM)

[fly_fisherman]

Still Under the Radar!!!

$VDRM

OTC stocks galore diluting with either zilch for revenues or revenues are Years Away!!! You can get a false run up but then a MIGHTY pullback without REVENUES and TOXICS ON THE BOOKS!!! VDRM IS REFRESHING WITH TODAY NO DEBIT/TOXICS AND GROWING REVENUES!! Time to separate the BEST from the REST in the OTC!!!

TODAYS TARGET IS 30-40 MILLION IN REVENUES for 2021. THIS IS JUST THE BEGINNING. AS THE PRODUCTS CONTINUE TO GAIN ACCEPTANCE WE ARE MERELY 3-5 CONTRACT AWAY FROM 100-200+ MILLION IN REVENUES!! MULTIPLE PRODUCTS AVAILABLE AS WELL. IT IS WHAT IT IS AND ITS TODAY!!! NOT WAITING ON AN ACQUISITION OR R/M. We have all been down that path. NOT WAITING ON FDA APPROVAL FROM TRIALS 2 YEARS FROM NOW. We have all been down that path too.

WE ARE TODAY. THE TIMING IS RIGHT AND IT IS NOW!!!

UNDER A NICKEL EVEN A DIME IS DIRT CHEAP!! FDA APPROVED IP TODAY!!

No Toxics or Debt (Very Refreshing!)
No Dilution (Very Refreshing!)
CEO States no need for Toxic financing going forward!!!
Pink "Current"
Up List OTCQB coming!
Revenues today - CEO states "Just scratching the surface"
30-40 million 2021 revs 500,000 units mfg already paid for-VERY NICE!!!
FDA Approved IP - Patent Protected
Domestic/Global Coming!
Hospitals/Insurance Carriers - HUGE

SS 04/06/2021 - Strong SS
A/S: 1 Billion
O/S: 981 Million
Restricted: 73,956,186
Unrestricted: 907,100,265
Held at DTC: 863,735,749

========UPDATES/NEWS==========

ViaDerma, Inc. Provides Preliminary Revenue Estimates and Highlights for its Record Breaking 1st Quarter
The Company realized significant Q1 revenue growth due to increased online retail sales and proceeds from a licensing agreement

The Company paid off all outstanding toxic convertible debt and is now completely debt free. Additionally, ViaDerma expects to self-fund all operations from this point and does not expect to take on any future debt.
**** ABSOLUTELY HUGE... They KNOW what is coming!!!

At the request of ViaDerma, OTC Markets conducted a manual review of the Company’s “shell risk” status and as a result has removed the “shell risk” annotation from ViaDerma’s profile.
**** VERY NICE CLEANUP EFFORTS - Getting their ducks in a row!!!

ViaDerma intends to submit an application this year for listing to the OTCQB. To qualify for OTCQB listing the Company needs to have one-year audited financials and add two independent directors. ViaDerma is currently seeking a qualified auditing firm that is registered with the Public Company Accounting Oversight Board (PCAOB) and is conducting a search for suitable directors.
**** NICE VERY NICE!!!

FROM THE CEO:

“While I am very pleased with the growth we have experienced in the first quarter, we have not yet even scratched the surface of our potential,” said Dr. Chris Otiko, ViaDerma President and CEO. “Vitastem is a great product and the results experienced by its users is likely the main reason for our increased online retail sales. However, our top priority this year is to focus on large institutions and integrated delivery networks. Our marketing reps have been working closely with several prospective institutional clients and we hope to finalize some large purchase orders in the near future.”

https://www.otcmarkets.com/stock/VDRM/news/story?e&id=1858541

Viaderm, Inc. Announces the Payment of all Toxic Convertible Notes and Has Become Debt Free
Press Release

https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Inc-Announces-the-Payment-of-all-Toxic-Convertible-Notes-and-Has-Become-Debt-Free?id=293822

ViaDerma Poised for Explosive Growth in 2021

https://boherald.com/viaderma-poised-for-explosive-growth-in-2021/

ViaDerma Inc., Provides Review of 2020 and Looks Forward to 2021

Some of the highlights of the past 12 months include: (ALL HUGE DEVELOPMENTS)

The FDA approved the registration of a new 55 ml Vitastem spray bottle. This came at the request of hospitals that have tested the product. A larger spray version will be easier to apply the medication to large wounds.

Liberdol, a new relief pain product was officially launched in 2020. The analgesics market in the U.S. is estimated to be more than $12 billion dollars.
*** 12 billion target market for Liberdol alone!

An extended line of credit was secured for financing future manufacturing. We anticipate sales to top 500,000 units in 2021.
*** Line of credit!! You don't just get that in the OTC.(Like a small cap)

A large national hospital chain and a major health insurance company have completed successful testing of the Vitastem product. We are now in the final stages of discussions to determine the size of the initial purchase.
*** Get Insurance Companies/Institutions on board the SKY IS THE LIMIT!

Successful product testing was completed by a major midwestern university with whom we are also in discussions regarding their initial product purchase.
*** BOOM!!!

We have initiated discussions with a major global medical nonprofit that has expressed interest in purchasing Vitastem for use by their doctors and medical staff in treating patients.
*** Marketing efforts truly just ramping UP!

https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Inc-Provides-Review-of-2020-and-Looks-Forward-to-2021?id=286028

THIS IS ALL IMHO and HOW I SEE IT. REVIEW THE DD OUT THERE AND MAKE YOUR OWN DECISION!!